Evidence map›Paper›PMID 42289700›Full record

ReviewExperimental hematology & oncology2026

Rewiring tumor metabolism: heterogeneity, oncometabolites, and adaptive plasticity.

Jianqiang Yang, Catherine C Zhou, Soumya Vijaya Kumar, Chloe Shay, Yong Teng

Abstract readReview
In one paragraph

Review in Experimental hematology & oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jianqiang YangDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, 30322, USA.
Catherine C ZhouWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, 30322, USA.
Soumya Vijaya KumarDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, 30322, USA.
Chloe ShayWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, 30322, USA.
Yong TengDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, 30322, USA. yong.teng@emory.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic reprogramming is a well-established hallmark of cancer, driven by oncogenic mutations and microenvironmental pressures to support rapid proliferation and adaptation to stress. This reprogramming is not uniform but instead exhibits profound metabolic heterogeneity, with distinct tumor subpopulations and spatial niches relying on divergent metabolic pathways such as glycolysis, oxidative phosphorylation, and nutrient scavenging. This heterogeneity evolves dynamically during tumor progression and in response to therapy, driven by genetic and epigenetic alterations, hypoxia, nutrient gradients, and therapeutic influences. Critically, it contributes to major clinical challenges by promoting immune evasion through nutrient competition and the accumulation of immunosuppressive metabolites, and by fostering therapy-tolerant cell states. A deeper understanding of the spatiotemporal dynamics of tumor metabolism and their functional consequences reveals novel therapeutic vulnerabilities. This review examines the origins and biological implications of metabolic heterogeneity, discusses strategies to overcome therapeutic resistance by targeting context-specific metabolic dependencies or by combining metabolic inhibitors with immunotherapy, and highlights the potential of patient stratification based on metabolic profiles. Ultimately, elucidating this metabolic complexity is essential for the development of innovative, personalized therapeutic approaches that improve outcomes in cancer treatment.

Indexed as

Metabolic heterogeneityMetabolic reprogrammingOncometabolitesPersonalized treatmentThe tumor microenvironmentTumor metabolism

Identifiers

PMID42289700
PMCPMC13523484

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.